What IBSA PHARMA INC does

IBSA Pharma Inc. is the US commercial subsidiary of IBSA Group (Institut Biochimique SA), a Swiss multinational pharmaceutical company founded in 1945 in Lugano, Switzerland. The company develops and commercializes pharmaceutical products across 10 therapeutic areas, with its US operations focused on Endocrinology, Pain and Inflammation, and Urology. Its portfolio is differentiated by two proprietary drug delivery technology platforms: FilmTec, an advanced pharmaceutical formulation technology, and Topical Patch Technology, a targeted, patient-centered delivery system for pain and inflammatory conditions. The company maintains a registered FilmTec trademark and operates under a four-pillar framework (Person, Innovation, Quality, Responsibility) aligned with ESG goals.

The US subsidiary is headquartered in Parsippany, New Jersey, and sells through established pharmaceutical distribution channels as well as the proprietary IBSA Direct program. The parent group reaches 90 countries across 5 continents through 20 wholly-owned subsidiaries in Europe, China, and the United States, employing 2,500+ people worldwide. Its go-to-market is sales-led, relying on prescription and medical channels rather than disclosed direct-to-consumer or platform models, and pricing is not publicly disclosed. Customer segments are defined by therapeutic use case (endocrine, pain/inflammation, urology patients) rather than enterprise logos.

Revenue is generated through one-time sales of prescription pharmaceutical products across multiple therapeutic areas. The company's value proposition centers on advanced drug delivery technologies enabling targeted, patient-centered solutions, supported by an 80+ year heritage, a global subsidiary network, and an associated IBSA Foundation that funds scientific research and fellowships. No public listing, funding rounds, M&A activity, or leadership changes are disclosed in the available sources.

Name

IBSA PHARMA INC

Legal name

IBSA Pharma Inc.

Website

https://ibsapharma.com

Company type

Private

Founded year

1945

Operating status

Operating

Short description

IBSA Pharma Inc. is the US subsidiary of Swiss multinational IBSA Group, commercializing prescription pharmaceuticals in endocrinology, pain and inflammation, and urology via proprietary FilmTec and topical patch drug delivery technologies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Products

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Pharmaceutical products
• Endocrine treatments
• Pain management drugs
• Urology therapeutics
• Topical drug delivery

Headquarters

HQ city

Parsippany

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: IBSA Pharma Inc. generates revenue through the sale of pharmaceutical products across multiple therapeutic areas including endocrinology, pain and inflammation, and urology. Products are distributed through subsidiaries and partners in 90 countries across 5 continents.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

IBSA Pharma Inc. is the US subsidiary of Swiss multinational IBSA Group (Institut Biochimique SA), founded in 1945. The company develops, manufactures, and commercializes pharmaceutical products across 10 therapeutic areas, with US market focus on Endocrinology, Pain and Inflammation, and Urology. It leverages proprietary drug delivery platforms including FilmTec® technology and topical patch systems to deliver targeted, patient-centered therapies distributed through its global subsidiary network and the IBSA Direct access program.

Product overview

IBSA Pharma Inc. is a Swiss multinational pharmaceutical company offering a portfolio of products across 10 therapeutic areas. The company focuses on Endocrinology, Pain and Inflammation, and Urology in the US market. IBSA develops proprietary drug delivery technologies including FilmTec® Technology and Topical Patch Technology. Products are distributed through the IBSA Direct program and reach over 90 countries globally through 20 subsidiaries.

Differentiator

Problem solved

Functional benefit

Products and services

• Endocrinology Products

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• IBSA FoundationcoreOthersIBSA Foundation is a separate organization that supports scientific research through fellowships and awards. The foundation honors researchers and promotes innovation in science and medicine, contributing to IBSA's reputation and talent network.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Almirall: Spanish-listed specialty pharma with strong dermatology and pain portfolios and European commercial roots. Comparable in mid-size specialty positioning and therapeutic breadth.
• Recordati: Italian specialty pharma operating across endocrinology, urology, and pain with established global subsidiaries. Comparable in therapeutic categories, mid-cap scale, and European heritage with US operations.
• Gedeon Richter: Hungarian specialty pharma with branded women's health, endocrinology, and CNS franchises. Comparable in mid-cap scale, branded specialty positioning, and direct European-to-US commercialization pathway.
• UCB: Belgian specialty pharma focused on neurology, immunology, and rare diseases. Comparable in mid-cap branded specialty positioning and global subsidiary distribution.
• Lundbeck: Danish specialty pharma with a focused branded portfolio and global direct-to-market presence. Comparable in mid-cap scale, specialty/branded positioning, and multi-country subsidiary distribution model.
• Ferring Pharmaceuticals: Privately-held Swiss-headquartered specialty pharma with overlapping therapeutic focus in reproductive medicine, urology, and endocrinology. Closely comparable in structure (private, mid-size, Swiss heritage), therapeutic portfolio, and global subsidiary model.
• Chiesi Farmaceutici: Private, family-owned European specialty pharma with a multi-therapeutic-area portfolio and direct presence in the US. Comparable in ownership structure (private group, wholly-owned subsidiaries), breadth of therapeutic areas, and mid-size global footprint.
• STADA Arzneimittel: German specialty and generics group with broad European footprint and growing branded specialty portfolio. Comparable in multi-country subsidiary model and European private-equity-backed ownership structure.
• Ipsen: French-listed specialty pharma with a focused multi-therapeutic portfolio including urology and pain. Comparable in mid-size specialty positioning, therapeutic area focus, and global commercial footprint.

Broad incumbents

• Merck KGaA (Healthcare): German science and technology group with a Healthcare division overlapping in fertility, endocrinology, and specialty pharma. Comparable in therapeutic areas and Swiss-quality-adjacent heritage, but materially larger and publicly listed.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/ibsausa

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IBSA PHARMA INC